MedTrace Logo

A Study Of PF-03882845 Absorption In Healthy Volunteers Given Orally As Tablet Versus Suspension Formulations And Effect Of Food On Its Absorption

NCT01366287 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2011-06-06

No results posted yet for this study

Summary

The primary purpose of this study is to estimate the relative bioavailability and food effect of a PF-03882845 tablet as compared to a suspension formulation used in previous clinical studies.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

PF-03882845

25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition

DRUG

PF-03882845

25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fasted condition

DRUG

PF-03882845

25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fed condition

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01366287 on ClinicalTrials.gov